Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc.
M.D. Anderson Cancer Center
OHSU Knight Cancer Institute
University of Chicago
EMD Serono
Roswell Park Cancer Institute
University of Southern California
University of Chicago